Diabetes
New oral obesity drug safe, linked to weight loss in first-in-human study
In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.
FDA clears implantable CGM with sensor that lasts up to 1 year
The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release.
Research needed to create ‘robust, conclusive’ evidence to manage preprocedural GLP-1 use
The use of glucagon-like peptide-1 receptor agonists exponentially increased in recent years for treating diabetes and obesity, with benefits also observed in other cardiometabolic syndromes.
GIs clash with GLP-1 restrictions for endoscopy, but ‘anesthesiologists have final say’
The explosive popularity of glucagon-like peptide-1 receptor agonists for diabetes and weight loss may have revolutionized obesity management, but their widespread use has also sparked concerns — and ignited a turf war — in the endoscopy suite.
Finerenone benefits in heart failure consistent regardless of diabetes status
In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.
Prevalence of atrial fibrillation in US adults much higher than previous estimates
Nearly one in 20 adults in the U.S. are estimated to have atrial fibrillation, many more than previous studies had indicated, according to new data out of the University of California, San Francisco.
Food insecurity, socioeconomic development influence global prevalence of MASLD
Country-specific public health policies that target metabolic dysfunction-associated steatotic liver disease risk factors, such as food insecurity and physical activity, may play a key role in mitigating the global burden of disease.
QWINT: Once-weekly insulin tied to similar HbA1c reduction as insulin degludec
Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog.
National Kidney Foundation launches patient-tailored learning tool for people with CKD
The National Kidney Foundation launched a new interactive portal that lets patients with chronic kidney disease learn more about their condition, according to a press release.
Tubeless insulin patch pump receives FDA clearance for type 1 and type 2 diabetes
The FDA has granted 510(k) clearance for an insulin patch pump for adults with type 1 or type 2 diabetes, Embecta Corp. announced.